Lifecore Biomedical stockholders will vote on December 23, 2026 on a merger that would make the company a wholly owned subsidiary, paying $6.28 per common share in cash plus one contingent value right.
LFCR · Lifecore Biomedical, Inc. De
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
The Department of Justice and Federal Trade Commission granted early termination of the HSR Act waiting period effective November 4, 2026, satisfying a closing condition for Lifecore Biomedical’s merger. Stockholder approval and other conditions remain.
Lifecore Biomedical’s merger cleared the antitrust waiting period on November 4, 2026, satisfying a closing condition; the transaction still requires stockholder approval and other remaining conditions.
Lifecore entered a merger agreement with affiliates of Webster Equity Partners on September 27, 2026 as nine-month revenue fell $23.0 million. All 50,187 Series A Preferred Stock shares were tendered for redemption, scheduled for December 28, 2026.
Lifecore Biomedical reported third-quarter revenue of $25.3 million, down 18.6%, and net loss of $40.1 million for the period ended September 30, 2026. Nine-month revenue was $82.7 million, down 21.8%; liquidity totaled approximately $38.0 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q1 FY26 earnings call · May 6, 2026TL;DR. Q1 revenue, gross profit and adjusted EBITDA deteriorated year over year, with much of the previously disclosed headwind front-loaded into the first half. However, management reaffirmed 2026 revenue and adjusted EBITDA guidance, signed three commercial site transfers expected to contribute in 2028, reduced expenses, improved liquidity and entered Q2 with all orders in and revenue visibility of roughly 32 to 34 million.
- + Management reaffirmed 2026 revenue guidance of $120 to $125 million and adjusted EBITDA guidance of $20.5 to $25 million.
- + The three newly signed commercial site-transfer programs are expected to generate mid-seven-figure opportunities and commercial revenue in 2028. new
- + SG&A and R&D expenses declined for a sixth consecutive quarter, bringing cumulative reductions since late 2024 to almost $8 million. new
- + All second-quarter orders were in, providing visibility to revenue in the roughly 32 to 34 million range. new
- + LifeCore is preparing for its largest customer's commercial demand to double beginning in 2027. new
- + Liquidity improved to approximately $38 million. new
- − First-quarter revenue fell 34%, declining 12 million to $23.2 million from $35.2 million. new
- − Gross profit fell 5.4 million to $4.5 million from $9.8 million. new
- − Adjusted EBITDA fell 4.7 million to $1 million from $5.7 million. new
- − A Q1 revenue miss was shifted into Q2. new
- − Approximately 50% of the previously disclosed headwind affected Q1, with roughly 80% expected to flow through first-half results. new
- − Management's 2026 guidance includes a net loss of $35.4 to $30.9 million. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $9.6M | six months ended June 30, 2026 | — |
| Early-Mid Stage Projects | 22 | as of June 2026 | — |
| Employees | 400 | Lifecore at a Glance | — |
| Free cash flow non-GAAP | $880K | Six months ended June 30, 2026 | — |
| Late Stage Projects | 16 | as of June 2026 | — |
| liquidity | $38.8M | second quarter of 2026 | — |
| New business wins in the last twelve months | 13 | last twelve months | — |
| Sq. Ft. Facility | 248,000 | Lifecore at a Glance | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LFCR
this stock
Lifecore Biomedical, Inc. De
|
$242.60M | -21.8% | +6.4% | — | 4.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.96B | +36.4% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$51.90B | +7.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.28B | +35.3% | +4.3% | 96.0 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 20
Lifecore Biomedical stockholders will vote on December 23, 2026 on a merger that would make the company a wholly owned subsidiary, paying $6.28 per common share in cash plus one contingent value right.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LFCR | +0.0% | +0.5% | +27.5% | +0.0% | -21.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +3.9% | +6.0% | +31.0% | +3.4% | -28.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.